A ‘landmark’ clinical trial called the AMP study launches on three continents to test HIV-blocking super antibodies
April 7, 2016
| By Mary Engel / Fred Hutch News Service
“It’s not often that you know that you’re starting a landmark study," says Dr. Larry Corey, founder and director of the HIV Vaccine Trials Network. Two of the world’s top HIV prevention clinical trial networks have joined forces to test an experimental antibody that could potentially protect people from infection by almost all strains of the rapidly mutating AIDS virus.